tradingkey.logo
tradingkey.logo
Suchen

Bausch + Lomb Corp

BLCO
Zur Watchlist hinzufügen
16.540USD
-0.090-0.54%
Handelsschluss 06/30, 16:00ETKurse um 15 Minuten verzögert
5.86BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Bausch + Lomb Corp Unternehmen

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Bausch + Lomb Corp Informationen

BörsenkürzelBLCO
Name des UnternehmensBausch + Lomb Corp
IPO-datumMay 06, 2022
CEOSaunders (Brenton L)
Anzahl der mitarbeiter13500
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse520 Applewood Crescent
StadtVAUGHAN
BörseNASDAQ OMX NASDAQ Basic NYSE
LandCanada
PostleitzahlL4K 4B4
Telefon19082552864
Websitehttps://ir.bausch.com/
BörsenkürzelBLCO
IPO-datumMay 06, 2022
CEOSaunders (Brenton L)

Führungskräfte von Bausch + Lomb Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
87.02K
-1.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
72.80K
-18.77%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
87.02K
-1.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
72.80K
-18.77%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Bausch + Lomb Corp?

Die fünf größten Anteilseigner von Bausch + Lomb Corp sind: Mr. Luc Bonnefoy

Wie viele Institutionen halten Anteile an Bausch + Lomb Corp (BLCO)?

Mit Stand vom 2026Q1 halten 249 Institutionen Anteile an Bausch + Lomb Corp, mit einem Gesamtmarktwert von etwa 40.30M, was 11.30% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -25007155.00 gestiegen.

Was ist die größte Einnahmequelle von Bausch + Lomb Corp?

Am 2026Q1 erzielte das Geschäft mit Devices für Bausch + Lomb Corp den höchsten Umsatz in Höhe von 1.92B, was 37.68% des Gesamtumsatzes entspricht.
KeyAI